Skip to main content
Clinical Trials/CTRI/2018/02/012148
CTRI/2018/02/012148RecruitingPhase 2

The Role of Fecal Microbiota Transplantation for maintenance of remission in patients with ulcerative colitis

Arshdeep Singh0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Confirmed Ulcerative Colitis patients who are in clinical remission (defined as complete resolution of symptoms) for a minimum duration of 6 months.
  • 2. Patients must be on stable medication regimen for at least 6 months prior to enrollment.
  • 3. Able to give informed consent and/or assent as appropriate

Exclusion Criteria

  • 1. Patients with active disease
  • 2. Patients having toxic megacolon
  • 3. Treatment naïve patients
  • 4. Pregnant and lactating ladies
  • 5. Prior colectomy
  • 6. Positive stool test for any of the following: Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, E. coli by standard stool culture.
  • 7. Regular probiotic supplement use within prior 4 weeks to enrollment
  • 8. Severe immunodeficiency, inherited or acquired (e.g. HIV, chemotherapy, or radiation therapy)
  • 9. Patients unwilling or unable to give consent or participate in all study requirements

Investigators

Sponsor
Arshdeep Singh

Similar Trials

Stool transplant as treatment in... | Clinical Trial